Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 3/20 | 0.58 |
| ▸ | AKT2 | P31751 | 5/20 | 0.56 |
| ▸ | BTK | Q06187 | 5/20 | 0.49 |
| ▸ | JAK3 | P52333 | 3/20 | 0.46 |
| ▸ | JAK2 | O60674 | 3/20 | 0.46 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.45 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.45 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1050199 | 1.00 | KIT (0.58) | KITAKT2BTKJAK3JAK2 | |
| SCHEMBL10320291 | 0.89 | BTK (0.56) | KITAKT2BTKJAK3JAK2 | |
| SCHEMBL1046808 | 0.89 | BTK (0.56) | KITAKT2BTKJAK3JAK2 | |
| SCHEMBL12957998 | 0.87 | JAK2 (0.56) | KITAKT2BTKJAK3JAK2 | |
| SCHEMBL1049144 | 0.87 | JAK2 (0.56) | KITAKT2BTKJAK3JAK2 | |
| SCHEMBL10316833 | 0.87 | JAK2 (0.56) | KITAKT2BTKJAK3JAK2 | |
| SCHEMBL12958805 | 0.87 | KIT (0.48) | KITAKT2JAK3JAK2JAK1 | |
| SCHEMBL10321504 | 0.85 | KIT (0.53) | KITAKT2JAK3JAK2JAK1 | |
| SCHEMBL1049106 | 0.85 | KIT (0.53) | KITAKT2JAK3JAK2JAK1 | |
| SCHEMBL10317041 | 0.84 | KIT (0.65) | KITAKT2BTKJAK3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346809-B2 | Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors | LEO PHARMA A/S (DK) | 2016-05-24 | — | — | US | disclosed |
| US-9346809-B2 | Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors | LEO PHARMA A/S (DK) | 2016-05-24 | — | — | US | disclosed |
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2012-07-12 | — | — | US | disclosed |
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | JAK1, JAK2, JAK3 | KIT 327/4885AKT2 703/4885BTK 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.